image: This is a picture of the cover image. view more
Credit: Future Science Group
Future Science Group (FSG) today announced the publication of a new article in the Journal of Comparative Effectiveness Research, discussing the recent recommendations from the Center for Medical Technology Policy's (CMTP) Green Park Collaborative (GPC-USA). The recommendations, released in August, discuss the conduct of studies that compare sequences of therapies in areas of advanced and metastatic cancer where a range of therapeutic options exist, but evidence is lacking on the optimal choices for sequential or combination therapy.
As the article discusses, current preferences for treatment order are developed in ways that can be lengthy and inefficient. However, these decisions are crucial for the patient as they can influence the course of disease, patient quality of life and ultimately patient survival.
It was against this backdrop that the GPC-USA selected this as a priority topic. In a new editorial article, Dr Donna Messner, Vice President and Senior Research Director at the CMTP, and GPC-USA Oncology Consortium Lead, describes the framework the GPC-USA developed to address the challenge and their recommendations for more rapid assessment of the comparative effectiveness of oncology treatment sequences.
"The recommended approach can fill evidence gaps between traditional clinical trials, especially as real-world data sources become more robust. At the same time, it puts the spotlight on new kinds of patient-important outcomes that traditional trials largely have not measured; these types of outcomes are starting to be recognized as important." commented Donna Messner.
"The recommendations released by the GPC-USA in August provide a valuable resource for the oncology community, who are making difficult decisions regarding treatment sequences", commented Laura Dormer, Managing Editor of the Journal of Comparative Effectiveness Research. "We are delighted to feature an article discussing the recent recommendations and how they were developed, and look forward to seeing the further discussion they will inevitably generate."
###
The article is available free to read at: http://www.futuremedicine.com/doi/full/10.2217/cer.15.47
About Journal of Comparative Effectiveness Research
The goal of comparative effectiveness research is to assist patients, physicians, purchasers and policymakers to choose between the available effective treatments in order to improve healthcare delivery at the level of the individual and on a population scale. The underlying question in undertaking comparative effectiveness research is - which treatment will work best, in which patient, and under what circumstances? Journal of Comparative Effectiveness Research (IF: 0.719), launched in 2012, provides stakeholders with the key data and opinions to make informed and specific decisions on clinical practice.
About Future Science Group
Founded in 2001, Future Science Group (FSG) is a progressive publisher focused on breakthrough medical, biotechnological and scientific research. FSG's portfolio includes two imprints, Future Science and Future Medicine. In addition to this core publishing business, FSG develops specialist eCommunities. Key titles and sites include Bioanalysis Zone, Epigenomics, Nanomedicine and the award-winning Regenerative Medicine. The aim of FSG is to service the advancement of clinical practice and drug research by enhancing the efficiency of communications among clinicians, researchers and decision-makers, and by providing innovative solutions to their information needs. This is achieved through a customer-centric approach, use of new technologies, products that deliver value-for-money and uncompromisingly high standards. http://www.future-science-group.com
Journal
Journal of Comparative Effectiveness Research